MDM2 and breast cancer: In addition, as FKBP1A degrades MDM2, it makes cells susceptible to chemotherapy-induced apoptosis; in breast cancer patients with high MDM2 expression, FKBP1A elevated sensitivity to anthracycline chemotherapeutic agents [7,8].